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Abstract
HIV infects macrophages and microglia in the central nervous system (CNS), which express lower
levels of CD4 than CD4+ T cells in peripheral blood. To investigate mechanisms of HIV
neurotropism, full-length env genes were cloned from autopsy brain and lymphoid tissues from 4
AIDS patients with HIV-associated dementia (HAD). Characterization of 55 functional Env clones
demonstrated that Envs with reduced dependence on CD4 for fusion and viral entry are more frequent
in brain compared to lymphoid tissue. Envs that mediated efficient entry into macrophages were
frequent in brain, but were also present in lymphoid tissue. For most Envs, entry into macrophages
correlated with overall fusion activity at all levels of CD4 and CCR5. gp160 nucleotide sequences
were compartmentalized in brain versus lymphoid tissue within each patient. Proline at position 308
in the V3 loop of gp120 was associated with brain compartmentalization in 3 patients, but
mutagenesis studies suggested that P308 alone does not contribute to reduced CD4 dependence or
macrophage-tropism. These results suggest that HIV adaptation to replicate in the CNS selects for
Envs with reduced CD4 dependence and increased fusion activity. Macrophage-tropic Envs are
frequent in brain but are also present in lymphoid tissues of AIDS patients with HAD, and entry into
macrophages in the CNS and other tissues is dependent on the ability to use low receptor levels and
overall efficiency of fusion.
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Introduction
Human immunodeficiency virus type 1 (HIV) infects the central nervous system (CNS) in the
early stages of disease (An et al., 1999;Davis et al., 1992) and causes HIV-associated dementia
*Corresponding Author. Mailing Address: Dana-Farber Cancer Institute, JFB 816 44 Binney St. Boston, MA 02115 Phone: (617)
632-2154 Fax: (617) 632 3113 E-mail: dana_gabuzda@dfci.harvard.edu
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers
we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting
proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could
affect the content, and all legal disclaimers that apply to the journal pertain.
NIH Public Access
Author Manuscript
Virology. Author manuscript; available in PMC 2008 March 30.
Published in final edited form as:
Virology. 2007 March 30; 360(1): 105–119.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
(HAD) or milder forms of neurocognitive impairment in 10–20% of AIDS patients (Gonzalez-
Scarano and Martin-Garcia, 2005;Kaul et al., 2001;Kaul et al., 2005;McArthur et al.,
2003;Sacktor et al., 2002). Highly active anti-retroviral therapy (HAART) has reduced the
incidence of HAD (d'Arminio Monforte et al., 2004;Dore et al., 1999;Sacktor et al.,
2001;Sacktor et al., 2002), but the prevalence of minor cognitive and motor disorders (MCMD)
has been increasing as HIV-infected individuals survive for a longer time on anti-retroviral
therapies (Dore et al., 2003;McArthur et al., 2003;Neuenburg et al., 2002;Valcour et al.,
2004). Most current antiviral drugs have relatively poor CNS penetration. Thus, the CNS is an
important reservoir for long-term viral persistence and neurocognitive impairment continues
to be a significant complication of HIV disease.
HIV enters the CNS via trafficking of infected monocytes and lymphocytes across the blood-
brain barrier (reviewed in (Dunfee et al., 2006a;Gonzalez-Scarano and Martin-Garcia, 2005).
The main target cells for HIV infection in the CNS are macrophages and microglia. HIV entry
is initiated by the viral envelope glycoprotein gp120 binding to CD4. Structural rearrangements
induced by CD4 binding allow subsequent interaction with a chemokine coreceptor, usually
CCR5 or CXCR4, leading to further conformational changes and fusion of viral and target cell
membranes (Deng et al., 1996;Dragic et al., 1996;Oberlin et al., 1996;Trkola et al., 1996;Wu
et al., 1996). Coreceptor usage is a major determinant of cellular tropism. CCR5 using (R5)
viruses infect CD4+ T cells and macrophages, and CXCR4 using (X4) viruses infect CD4+ T
cells and T cell lines. However, CCR5 usage alone does not predict macrophage tropism (M-
tropism) (Cheng-Mayer et al., 1997;Cunningham et al., 2000;Dittmar et al., 1997;Gorry et al.,
2001;Hung et al., 1999). A subset of R5 viruses do not productively infect macrophages (Gorry
et al., 2001;Li et al., 1999). Furthermore, some M-tropic HIV strains use CXCR4 for entry in
macrophages and microglia (Ancuta et al., 2001;Gorry et al., 2001;Koning et al., 2001;Naif et
al., 2002;Simmons et al., 1998;Singh et al., 2001;Yi et al., 1999;Yi et al., 1998). Receptor
density also determines the susceptibility of primary cells and cell lines to HIV infection (Fear
et al., 1998;Kuhmann et al., 2000;Platt et al., 1998;Rana et al., 1997;Reynes et al., 2001;Tuttle
et al., 1998). Thus, while CCR5 is the main coreceptor for HIV entry in macrophages, viral
determinants independent of those that influence coreceptor usage also influence macrophage
tropism.
Macrophages and microglia express lower levels of CD4 than CD4+ T cells in peripheral blood
(Di Marzio et al., 1998;Dick et al., 1997;Graziani-Bowering and Filion, 2000;Jordan et al.,
1991;Kazazi et al., 1989;Lewin et al., 1996;Martin-Garcia et al., 2002;Peudenier et al.,
1991a;Peudenier et al., 1991b;Tuttle et al., 1998;Wang et al., 2002;Williams et al., 1992).
Previous studies identified a few brain-derived HIV viruses from HAD patients that replicate
efficiently in macrophages and microglia and have reduced dependence on CD4 and/or CCR5
levels for entry (Gorry et al., 2001;Gorry et al., 2002;Martin-Garcia et al., 2006;Peters et al.,
2004). Reduced CD4 or CCR5 dependence may therefore contribute to HIV neurotropism and
neurovirulence. However, whether HIV Envs that have reduced dependence on CD4 and CCR5
levels are more frequent in brain compared to other tissues remains unclear.
Genetic evolution of HIV within the brain is distinct from that in lymphoid tissues and other
organs (Chang et al., 1998;Donaldson et al., 1994;Gartner et al., 1997;Gorry et al.,
2001;Hughes et al., 1997;Korber et al., 1994;Shapshak et al., 1999;van't Wout et al.,
1998;Wong et al., 1997). Genetic compartmentalization of viral variants in the brain suggests
that adaptive evolution may occur in the CNS in response to unique constraints of the brain
microenvironment, such as different target cell populations and immune selection pressures.
Strain et al reported several residues in the C2-V3 region of Env associated with
compartmentalization in the cerebrospinal fluid (CSF) (Strain et al., 2005). However, other
studies failed to identify sequence differences associated with brain compartmentalization
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(Ohagen et al., 2003;Reddy et al., 1996), and Env sequences that enhance HIV neurotropism
have not been identified.
To investigate genetic and functional characteristics of Envs in brain versus lymphoid tissues,
full-length env genes were amplified from autopsy brain and lymphoid tissues from 4 AIDS
patients with HAD. Envs with reduced dependence on CD4 levels were more frequent in brain,
but were also present in lymphoid tissue. The capacity of Envs from both brain and lymphoid
tissues to mediate entry into macrophages correlated with overall fusion activity at all levels
of CD4 and CCR5. Proline at position 308 in the V3 region of gp120 was associated with brain
compartmentalization in 3 patients, but mutagenesis studies suggested that P308 alone did not
contribute to the reduced CD4 dependence or macrophage-tropism of brain-derived Envs.
Thus, HIV adaptation to replicate in the CNS microenvironment selects for Envs with reduced
CD4 dependence and increased fusion activity. Macrophage-tropic Envs are frequent in brain
but are also present in lymphoid tissues of HAD patients, and entry into macrophages is
influenced by the capacity to use low receptor levels and overall efficiency of fusion.
Results
HIV envelopes with reduced dependence on CD4 levels are more frequent in brain compared
to lymphoid tissues
To determine whether HIV Envs with reduced dependence on CD4 or CCR5 levels are more
frequent in brain compared to lymphoid tissues, full-length HIV env genes were cloned directly
from autopsy brain (frontal lobe or basal ganglia) and lymphoid (lymph node or spleen) tissues
from 4 AIDS patients with HAD (MACS2, MACS3, UK1, and UK7) (Table 1). Eight to 40
Env clones from each tissue sample were screened for functional activity in single-round
infection assays by pseudotyping onto NL43 env-GFP and detecting infection of CCR5/
CXCR4 positive Hela/CD4 cells (clone JC53). By this approach, 10 tissue samples from 4
AIDS patients yielded 55 functional Env clones (n=35 brain and 20 lymphoid). All 55 Env
clones used CCR5 to enter cells, 2 weakly used CCR3, and none used CXCR4 (Table 1). None
of the Env clones mediated CD4-independent infection in Cf2 cells expressing CCR5. This
pattern of coreceptor usage is consistent with the R5 phenotype of primary viruses previously
isolated from these tissue samples ((Gorry et al., 2001) and P. Gorry and D. Gabuzda,
unpublished data).
To investigate the frequency of Envs in brain versus lymphoid tissue that can use low levels
of CD4 or CCR5 to mediate fusion, we performed cell-to-cell fusion assays with Cf2 cells
expressing low (Mean Fluorescent Intensity (MFI) 18 (range 17–21) and 52 (range 35–86);
30% and 47% positive for CD4 and CCR5, respectively, as determined by flow cytometry),
medium (MFI 124 (116–132) and 178 (149–193); 55% and 69%), or high (MFI 773 (689–883)
and 516 (459–584); 76% and 78%) CD4 and CCR5. Envs from brain and lymphoid tissue from
the same patient were assayed simultaneously on the same populations of transfected Cf2 cells.
The well characterized ADA and YU2 Envs cloned from macrophage-tropic blood viral
isolates were used as controls in parallel experiments. For most Envs, fusion increased as CD4
and CCR5 levels increased, with greater levels of overall fusion for brain compared with
lymphoid Envs at all levels of CD4 and CCR5 (Fig 1A). To determine whether there are
differences between brain and lymphoid Envs in their relative use of low CD4 levels, we
calculated the ratio for Env-mediated fusion with cells expressing low versus high CD4 (Fig.
1B). MACS2 brain Envs (n=8) fused more efficiently with cells expressing low or medium
CD4 levels than did MACS2 lymphoid Envs (n=6) (Fig. 1A). Seven of 8 MACS3 brain Envs
and 7 of 8 UK7 brain Envs mediated fusion at low CD4 levels compared with only 1 of 6
MACS3 lymphoid Envs (LN2) and none of the UK7 lymphoid Envs (Fig. 1). In contrast, the
ability of UK1 brain versus lymphoid Envs to use low CD4 levels did not segregate according
to tissue of origin. Both brain (8/11) and lymphoid (3/6) (SP2, SP6-20, SP6-22) UK1 Envs
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mediated fusion at low CD4. In total, 30 of 35 brain Envs but only 4 of 20 lymphoid Envs
(p<0.01, Fisher’s Exact test) mediated fusion with cells expressing low CD4 levels.
In addition to mediating fusion at low CD4 levels, 11 UK1 Envs had an enhanced capacity to
induce fusion with cells expressing low CCR5 levels compared to MACS2, MACS3, and UK7
Envs (Fig. 1A). Furthermore, MACS2 and UK7 brain Envs were more efficient than lymphoid
Envs at mediating fusion at low CCR5 levels when CD4 was at low or medium levels. In
contrast, MACS3 brain Envs were only marginally more efficient than lymphoid Envs at
mediating fusion at low CCR5 levels, and only when CD4 levels were also low (Fig. 1A).
Therefore, 3 patterns emerged from analyses of Envs from these patients: 1) In MACS2 and
UK7, brain Envs were more efficient than lymphoid Envs at mediating fusion at low CD4 and
CCR5 levels; 2) In MACS3, brain Envs were more efficient than lymphoid Envs at mediating
fusion at low CD4 but not CCR5 levels; and 3) In UK1, Env clones from both brain and
lymphoid tissue had a markedly enhanced capacity to mediate fusion at low levels of CD4 and
CCR5.
To test the dependence of brain and lymphoid Envs on CD4 and CCR5 levels when mediating
virus infection, we performed single round virus entry assays with Cf2 cells expressing low,
medium, or high CD4 and CCR5. For these assays, we tested 33 genetically distinct Envs
exhibiting a range of abilities to use different CD4 levels similar to that of all Envs cloned from
the same tissue sample. Envs that used low CD4 levels in cell-to-cell fusion assays (Fig. 1)
also mediated detectable infection of cells expressing low CD4 levels in infection assays (Fig.
2). MACS2, MACS3, and UK7 brain Envs had a greater capacity to infect cells expressing
low CD4 than did lymphoid Envs. In contrast, infection mediated by UK1 Envs showed no
clear distinction between brain versus lymphoid Envs in the ability to use low CD4, similar to
results observed in fusion assays. All UK1 brain and lymphoid Envs, except spleen clone 20,
infected cells expressing low CD4 more efficiently than the majority of MACS3, UK1, and
UK7 brain or lymphoid Envs (Fig. 2). Brain Envs had higher infectivity ratios for cells
expressing low versus high CD4 compared to lymphoid Envs (2p<0.001, Wilcoxon Rank-Sum
Test, with combined data stratified by patient). When data from individual patients were
analyzed, only MACS3 showed a statistically significant difference between brain and
lymphoid Envs (2p=0.016). In contrast, no segregation between brain and lymphoid Envs was
observed for infection of cells expressing low versus high levels of CCR5 (data not shown).
However, similar to data obtained in cell-cell fusion assays, UK1 Envs from both brain and
lymphoid tissue efficiently used low levels of CCR5 to mediate infection, and brain Envs from
MACS2 and UK7 used low CCR5 more efficiently than lymphoid Envs (data not shown).
Western blot analysis of Env expression demonstrated some variability in levels of gp160
expression and processing (Fig. 3 and data not shown). However, these differences did not
correlate with differences in the ability to mediate fusion at low CD4 or CCR5 levels. These
results demonstrate that Envs that can use low levels of CD4 and CCR5 for fusion and infection
are more frequent in brain compared to lymphoid tissue from the same patient.
To assess the ability of brain and lymphoid Envs to mediate entry into macrophages, we
performed single round entry assays. Equivalent amounts of luciferase reporter viruses
pseudotyped with brain or lymphoid Envs were used to infect primary MDM. Both brain and
lymphoid Envs mediated a broad range of entry levels into MDM. Levels of Env-mediated
entry into MDM did not clearly segregate according to tissue of origin or reduced CD4
dependence. (Fig. 4A). UK1 Envs with a greatly enhanced capacity to use low CD4 and CCR5
levels, SP6-20 and BG3-13, also mediated high levels of entry into MDM, suggesting that their
reduced dependence on CD4 and CCR5 levels contributed to their increased M-tropism. Levels
of entry into MDM mediated by individual Env clones across the entire data set correlated with
their levels of overall fusion activity at low, medium, and high levels of CD4 (Fig. 4B).
Together, these results suggest that efficient entry into MDM is dependent on several factors
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that include the ability of Envs to use low receptor levels and additional factors that influence
the overall efficiency and kinetics of fusion.
Analysis of HIV Env sequences
To investigate genetic relationships between env genes in brain and lymphoid tissue, we
performed phylogenetic analysis of full-length gp160 nucleotide sequences. No stop codons
or frame shifts were observed in the env open reading frames. Env sequences from the MACS2,
UK1, and UK7 brain isolates previously obtained by PBMC coculture (Dunfee et al.,
2006b;Gorry et al., 2002) were included for comparison. gp160 sequences grouped by patient
were most closely related to other sequences from the same patient, with no evidence for
possible contaminants (Fig. 5). Distinct env populations according to tissue of origin confirmed
genetic partitioning of Env sequences between brain and lymphoid tissue (Fig. 5).
Unexpectedly, Env clones from the MACS2 primary brain isolate, which do not have reduced
CD4 dependence, clustered with lymphoid rather than brain Envs. In contrast, Env clones from
the UK1 and UK7 primary brain isolates, which have reduced CD4 dependence, clustered with
Env clones amplified directly from brain tissue. Deletions and insertions in gp41 from the UK1
and MACS2 brain isolate-derived Envs (Gorry et al., 2002) were rare in functional envs
amplified directly from tissues, with a truncation near the gp41 C-terminus observed only in
UK7 lymphoid clone 7–6. The number of predicted N-linked glycosylation sites in brain and
lymphoid Envs ranged from 23 to 28 in gp120, and 4 to 5 in gp41 (Table 2). There was no
consistent difference in the number or distribution of predicted N-linked glycans between brain
and lymphoid Envs. Screening for hypermutation in brain and lymphoid env genes was
performed using HYPERMUT to compare the rate of G to A transitions in each env sequence
compared to the tissue consensus (Rose and Korber, 2000). Overall, the hypermutation rate
was low (<5%) with no significant difference between brain and lymphoid env genes. However,
we excluded nonfunctional Env clones from the data set, which would likely exclude highly
mutated Env sequences. The highest frequency of G to A transitions compared to the tissue
consensus was seen in 3 UK1 envs, BG3-10, SP5-5 and SP5-11. Overall, these envs were the
most genetically distinct compared to other Envs from this patient (Fig. 5). These analyses
confirm genetic compartmentalization of full-length, functional Env sequences and underscore
the importance of viral genotype and phenotype analysis without prior in vitro amplification.
Proline at position 308 in the V3 loop of HIV gp120 is associated with brain Env
To identify specific amino acid residues that are more frequent in brain compared to lymphoid
Envs, we performed a signature pattern analysis of all gp160 amino acid sequences in the data
set using VESPA (Korber and Myers, 1992). Proline at position 308, immediately N-terminal
of the GPGR sequence in the crown of the V3 loop, was associated with compartmentalization
in brain across the entire data set (p<0.01, Fisher’s Exact test). Proline at position 308 was
present in 100% (27/27) of brain Envs, but only 28% (4/14) of lymphoid Envs in 3 patients
(MACS2, UK1, and UK7) (Fig. 6). All lymphoid Envs with proline at position 308 were from
UK1 (SP2, 20, 6–20, and 6–22). All MACS3 Env clones contained histidine at position 308.
The clade B consensus at position 308 is histidine, which is found in 53% of clade B V3
sequences, while proline is found at position 308 in only 14% of clade B V3 sequences
(n=23,516 (http://hiv.lanl.gov)). In 8 published studies of matched brain and lymphoid or blood
samples, proline at position 308 is present in a higher proportion of brain (69/135, 51.1%)
compared with lymphoid Envs (45/125, 36.8%) (n=13 subjects that had P308 in any Env,
p=0.01, Fisher’s Exact test) (Donaldson et al., 1994;Gartner et al., 1997;Korber et al.,
1994;Martin-Garcia et al., 2006;Morris et al., 1999;Peters et al., 2004; van't Wout et al.,
1998;Wang et al., 2001). Therefore, proline at position 308 in the V3 region of gp120 is more
frequent in brain than in lymphoid tissue.
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Reduced CD4 and CCR5 dependence of brain Envs is not altered by mutation of P308
To assess the influence of P308 on functional characteristics of brain-derived Envs,
mutagenesis was used to change the proline to histidine at this position in the MACS2 (FL8-12)
and UK7 (Br34) brain Env clones. We investigated whether introducing this mutation altered
the capacity of these Envs to mediate fusion or infection with cells expressing low CD4 or
CCR5 levels. The mutant Envs containing H308 were expressed and processed at levels similar
to those of the parental Envs (Fig. 7B). There was no significant difference in the efficiency
of fusion or infection of Cf2 cells expressing low, medium, or high CD4 or CCR5 when P308
was changed to histidine (Fig. 7A). Additionally, we found no consistent enhancement or
reduction of entry into MDM during single round infection assays using MDM from different
donors when the H308 mutation was introduced (Fig. 7C). Thus, P308 does not contribute to
the reduced CD4 dependence of these 2 brain-derived Envs.
Mutation of P308 in brain Envs does not alter sensitivity of brain Envs to entry inhibitors
Mutation of histidine to proline at position 308 in gp120 of a primary HIV isolate was reported
in a viral escape mutant that developed resistance to the small molecule CCR5 inhibitor AD101
(Kuhmann et al., 2004;Trkola et al., 2002). The resultant virus was still dependent on CCR5,
but contained amino acid substitutions that altered the manner in which Env interacts with
CCR5 (Marozsan et al., 2005;Trkola et al., 2002). A change from histidine to proline at position
308 conferred an ~500 fold increase in drug resistance in an Env from one subject (Kuhmann
et al., 2004). Therefore, we tested the sensitivity of viruses pseudotyped with Envs containing
P308 versus H308 to the CCR5 inhibitors AD101, TAK-779 and the anti-CCR5 MAb 2D7,
and the HIV fusion inhibitor T20. MACS2 and UK7 brain Envs showed no difference in
sensitivity to these inhibitors when P308 was changed to histidine (Table 3). Therefore, in the
context of 2 brain-derived Envs, P308 did not affect sensitivity to CCR5 inhibitors. Thus, the
contribution of proline at position 308 to development of resistance to coreceptor inhibitors is
context-dependent, and additional determinants may be necessary to generate resistance in
genetically different Envs from patients.
The brain is an immunologically privileged site with reduced selection pressure from cellular
and humoral immunity to constrain viral evolution. Viral adaptation to the brain
microenvironment can result in enhanced sensitivity to neutralizing antibodies (Martin et al.,
2001;Song et al., 2004). Therefore, we tested whether introducing the H308 mutation into the
UK7 and MACS2 brain Envs alters sensitivity to neutralization by monoclonal antibodies
directed against the CD4 binding site (b12), coreceptor binding site (17b and 19e), or gp41
(2F5), and by sera from 4 HIV-infected individuals. The UK7 brain Env was more sensitive
to b12 neutralization, but more resistant to neutralization by patient sera, compared with the
MACS2 Env (Table 3). The 17b and 19e MAbs targeting the coreceptor binding site did not
reach the IC50 for these Envs at the highest concentration tested (10 μg/ml) in the presence or
absence of sCD4 (data not shown). We found no difference in the sensitivity to b12, 17b, 19e,
or 2F5 neutralization in these Envs when P308 was changed to histidine. Additionally there
was no difference in neutralization sensitivity to sera from 3 HIV positive patients (Table 3).
However, MACS2 brain Env containing H308 was more resistant to neutralization by sera
from an HIV-infected patient (PS2) compared to the parental Env containing P308, with a 2-
fold increase in the IC50 (Table 3). Previous studies have demonstrated a proline substitution
at position 308 associated with enhanced neutralization sensitivity (Quinnan et al., 1999;Young
et al., 2004;Zhang et al., 2002) suggesting that alteration of this residue in some Envs may
increase exposure of neutralization sensitive epitopes. Thus, persistence and
compartmentalization of this mutation in the brain may be a consequence of lower neutralizing
antibody levels in the CNS compared to the periphery.
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Discussion
In this study, we characterized HIV Env clones from brain and lymphoid tissue of 4 AIDS
patients with HAD and demonstrated that Envs with reduced dependence on CD4 levels are
more frequent in brain compared with lymphoid tissue from the same patient. Thirty of 35
brain Env clones had reduced dependence on CD4 in cell-cell fusion and single round infection
assays, while only 4 of 20 lymphoid Envs had reduced CD4 dependence. Previous studies
identified HIV Envs with reduced dependence on CD4 levels only in brain (Gorry et al.,
2001;Gorry et al., 2002;Martin-Garcia et al., 2006;Peters et al., 2004). Here we report that 4
lymphoid Envs from 2 HAD patients (3 UK1 spleen Envs and 1 MACS3 lymph node Env)
have a similar phenotype. Furthermore, 5 brain Envs from UK1, UK7, and MACS3 do not
have reduced CD4 dependence. Thus, Envs with reduced CD4 dependence are more frequent
in brain, but are also present in lymphoid tissues of some AIDS patients with HAD. These
results contrast with previous reports that identified Envs with reduced CD4 dependence only
in brain (Martin-Garcia et al., 2006;Peters et al., 2004;Peters et al., 2006), a discrepancy that
may be explained in part by the larger number of functional Env clones analyzed in our study.
In addition to having reduced CD4 dependence, MACS2 and UK7 brain Envs were also more
efficient at utilizing low CCR5 compared with lymphoid Envs. Moreover, a subset of both
brain and lymphoid UK1 Envs had a greatly enhanced capacity to use low CCR5 compared to
Envs from the other 3 patients. The finding that Envs with reduced CD4 dependence are more
frequent in brain than in lymphoid tissues suggests that viral adaptation to the CNS
microenvironment selects for viruses with an enhanced capacity to enter cells expressing low
levels of these receptors. However, interpatient variability in the capacity of Envs with reduced
CD4 dependence to use low CCR5 suggests that complex interdependent relationships exist
between CD4 and CCR5 dependence, as has been described for primary HIV isolates (Kozak
et al., 1997;Platt et al., 1998).
Reduced CD4 dependence has been associated with increased macrophage tropism of HIV and
SIV (Bannert et al., 2000;Gorry et al., 2002;Peters et al., 2004;Puffer et al., 2002). Furthermore,
brain Envs with reduced CD4 dependence are macrophage-tropic (Gorry et al., 2002;Peters et
al., 2004). We found that UK1 Envs mediated higher levels of entry into MDM than Envs from
the other 3 patients, suggesting that their greatly enhanced capacity to use low CD4 and CCR5
levels contributed to their increased M-tropism. However, the ability of Envs across the entire
data set to mediate entry into MDM did not show a consistent correlation with reduced
dependence on CD4 or CCR5. Rather, the capacity of Envs from both brain and lymphoid
tissues to mediate entry into macrophages correlated with overall fusion activity at all levels
of CD4 and CCR5. The majority of productive entry into MDM results from virion fusion at
the plasma membrane. However, virion internalization in these cells also occurs via
macropinocytosis and vesicular uptake into the endocytic pathway (Marechal et al.,
1998;Marechal et al., 2001;Schaeffer et al., 2004). HIV entry via the endocytic pathway usually
does not lead to productive infection (Marechal et al., 1998). Thus, virus entry via this
alternative pathway is unlikely to account for the lack of consistent correlation between MDM
entry and reduced CD4 dependence. Together, these findings suggest that the M-tropism of
Env clones from brain and lymphoid tissue is dependent not only on the ability to use low
receptor levels, but also on additional factors that influence the overall efficiency of fusion.
Such factors may include the ability to utilize different isoforms or modified forms of CD4
and CCR5 expressed on MDM (Bannert et al., 2001;Farzan et al., 1999;Lynch et al.,
2006;Mummidi et al., 1998), efficiency of binding to cell surface virion attachment factors
such as syndecans and type C lectins (Baribaud et al., 2001;Saphire et al., 2001), and the kinetics
of gp120 conformational rearrangements and gp41 six-helix bundle formation (Platt et al.,
2005;Reeves et al., 2004).
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Functional env genes from brain and lymphoid tissue of 4 patients in our study showed distinct
tissue specific compartmentalization. However, envs from viruses isolated from brain of
MACS2, UK1, and UK7 by coculture with PBMC were distinct from sequences amplified
directly from brain tissue, suggesting that viral selection or adaptation occurred during
coculture. This was particularly evident for env genes from the MACS2 brain isolate (Br4, Br9
and Br13), which were more closely related to sequences amplified from MACS2 spleen than
from brain sequences. The phenotype of the MACS2 virus isolate Envs was also more similar
to that of lymphoid Envs from this patient, as these Envs did not exhibit reduced CD4/CCR5
dependence. Similarly, nef genes amplified from the MACS2 brain virus isolate were unlike
nef sequences directly amplified from brain tissue, but were similar to nef sequences from
lymphoid tissue (Agopian et al., In press). The isolation of this virus from MACS2 brain tissue
could be the result of selection in the PBMC coculture of virus present in contaminating blood
vessels that contained blood or lymphoid env sequences. UK1 envs were amplified from both
frontal lobe and basal ganglia regions of brain. The env genes from these brain regions were
genetically distinct, consistent with previous reports of genetically distinct HIV sequences in
different regions of brain (Morris et al., 1999;Salemi et al., 2005;Shapshak et al., 1999). The
basal ganglia is the brain region most severely affected by HIV encephalitis (Berger and Arendt,
2000;Berger and Nath, 1997;Brew et al., 1995). One basal ganglia Env, BG3-13, exhibited
enhanced entry into MDM, but other Envs cloned from this region did not exhibit enhanced
macrophage tropism or increased cytopathicity compared to those from matched frontal lobe.
Thus, other mechanisms are likely to explain the preferential susceptibility of this region to
HIV-induced neurological injury.
In our data set, proline at position 308 in the V3 region of gp120 was associated with brain
compartmentalization in 3 patients. P308 was present in 100% of brain Envs, but only 28% of
lymphoid Envs from these patients. We also found a higher frequency of P308 in brain (51%;
n=135) compared with matched non-brain (37%; n=125) Env sequences when we analyzed
data sets from several previous studies (p=0.01, Fisher’s Exact test) (Donaldson et al.,
1994;Gartner et al., 1997;Korber et al., 1994;Martin-Garcia et al., 2006;Morris et al.,
1999;Peters et al., 2004; van't Wout et al., 1998;Wang et al., 2001). Power et al reported an
association between the amino acid residues at positions 308 and 332 with clinical signs of
AIDS dementia (Power et al., 1995), but other studies have questioned the role of a specific
amino acid at position 308 in neutrotropism (Di Stefano et al., 1996). However, further
evidence implicating amino acid alterations at position 308 in viral adaptation to the CNS was
recently described in a comparison of CSF and plasma samples (Pillai et al., 2006;Strain et al.,
2005). In this study, proline at position 308 was present in Envs from 4 patients with
compartmentalized env sequences and proline was significantly correlated with CSF origin
(31/43 in CSF and 2/48 in plasma, p<0.001, Fisher’s Exact test) (Pillai et al., 2006). A proline
at position 308 was reported in V3 loop sequences from astrocytes but not macrophages/
microglia microdissected from brain of one HAD patient (Thompson et al., 2004), raising the
question of whether latent HIV within astrocytes may be the source of some sequences
amplified in our study. Our data combined with studies of matched CSF and plasma samples
imply that proline at position 308 in the V3 loop is a shared signature sequence resulting from
adaptation to the brain microenvironment in some HIV-infected individuals.
Position 308 lies at the tip of the V3 loop and thus may be involved in interaction with the
chemokine coreceptor. However, it is not a position used for genotyping Envs for CCR5 or
CXCR4 usage (Jensen et al., 2003;Resch et al., 2001). The importance of this residue in
modulating Env interactions with CCR5 was highlighted by an in vitro generated escape mutant
from the CCR5 small molecule inhibitor AD101, with a mutation of histidine to proline at
position 308 conferring resistance (Kuhmann et al., 2004;Marozsan et al., 2005;Trkola et al.,
2002). However, mutation of P308 to histidine in brain Envs from MACS2 and UK7 did not
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alter sensitivity to CCR5 inhibitors. This result suggests that escape from coreceptor inhibitors
resulting from alterations in single residues in HIV Env is context-dependent.
Molecular modeling of the JRFL gp120-CD4-CD4i Ab X5 complex crystal structure (2B4C)
with Swiss PDB Viewer (http://ca.expasy.org/spdbv) suggests that introduction of a proline at
position 308 induces minor conformational changes in V3 that result in a slightly more open
conformation of the V3 tip region (R. Dunfee and D. Gabuzda, unpublished data). This
conformation may allow for increased exposure of the coreceptor binding site or increased
exposure of neutralizing epitopes in the N-terminus of V3. Consistent with this model, P308
in conjunction with a methionine at position 309 has been implicated in inducing a more open
conformation of HIV Env, resulting in CD4 independence and increased elicitation of broadly
neutralizing Abs by a primary HIV Env (Quinnan et al., 1999;Young et al., 2004;Zhang et al.,
2002). Envs from MACS2 brain and UK1 brain and spleen contain the P308/M309 motif, but
did not mediate CD4-independent infection. However, mutagenesis of P308 to histidine in a
MACS2 brain Env decreased sensitivity to neutralizing sera. A microglia-adapted virus,
Bori-15, is also more sensitive to serum neutralization (Martin et al., 2001), suggesting that
adaptation of brain Envs to the reduced receptor levels on target cells in the brain may result
in enhanced exposure of neutralizing epitopes. In the periphery, sensitivity to neutralization
by serum antibodies would likely be lethal to an evolving virus. However, the CNS is an
immunologically privileged site, with lower neutralizing activity than plasma (Goudsmit et al.,
1987;Pillai et al., 2006). Therefore mutations such as P308 may persist in the CNS even if they
expose neutralization-sensitive epitopes. Understanding the selective pressures on evolution
of the HIV envelope glycoproteins within the brain microenvironment may facilitate not only
a better understanding of mechanisms that determine viral tropism for specific target cells and
neutralizing epitopes, but also the development of therapeutics to target neurological injury in
AIDS patients.
Materials and Methods
Tissue samples
MACS2 and MACS3 were participants in the Chicago component of the Multicenter AIDS
Cohort study (MACS) (Gorry et al., 2001;Gorry et al., 2002). Tissue samples from patients
UK1 and UK7 were obtained from the Edinburgh MRC HIV Brain and Tissue Bank (Western
General Hospital, Edinburgh, UK). Autopsy brain and lymphoid tissue samples were stored at
−80°C. Clinical characteristics of patients and tissue samples are shown in Table 1.
Cells
293T, Cf2th (a canine thymocyte cell line) (Choe et al., 1996), and HeLa clone JC53 expressing
high levels of CD4 and CCR5 (Platt et al., 1998), provided by D. Kabat), were cultured in
Dulbecco's modified Eagle medium supplemented with 10% (vol/vol) fetal bovine serum and
100 μg of penicillin and streptomycin per ml. Cf2-Luc cells (Etemad-Moghadam et al.,
2000), derived from Cf2th cells, stably express the firefly luciferase gene under the control of
the HIV long terminal repeat and were cultured in medium containing 0.7 mg/ml of G418
(Mediatech, Herndon, VA). Cf2/CD4/R5 cells stably expressing CD4 and CCR5 were cultured
in medium containing 0.4 mg/ml of G418, and 0.15 mg/ml hygromycin (Roche, Indianapolis,
IN). Monocyte derived macrophages (MDM) were purified from PBMC by plastic adherence
and cultured for 5 days in RPMI 1640 medium supplemented with 10% fetal bovine serum,
100 μg of penicillin and streptomycin per ml and 10 ng/ml macrophage colony stimulating
factor (R&D Systems, Minneapolis, MN.).
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PCR amplification, HIV Env cloning, and sequence analysis
Genomic DNA was extracted from tissue samples using Puregene DNA Purification kit (Gentra
Systems, Inc., Minneapolis, MN). HIV Gag DNA copy number per 106 cells was determined
with TaqMan Universal PCR Master Mix (Applied Biosystems, Foster City, CA) using the
following primers and probe: 793-gag-F5’GGTGCGAGAGCGTCAGTATTAAG3’, 911-
gag-R5’AGCTCCCTGCTTGCCCATA3’ and 835-gag-
probe5’TGGGAAAAAATTCGGTTAAGGCCAGGG. Full-length Env genes were amplified
from genomic DNA and cloned into pCR3.1 as described (Gorry et al., 2002). Env clones were
sequenced using DYEnamic ET Terminator Cycle Sequencing kit (GE Healthcare, Piscataway,
NJ) on an Applied Biosystems 3100 Genetic Analyzer (Foster City, CA).
Western blot
Analysis of Env expression was performed as described (Gorry et al., 2002). Briefly, 293T
cells were transfected with pCR3.1Env clones and 72 h after transfection were rinsed twice in
PBS and resuspended in lysis buffer (Gorry et al., 2002). Equal amounts of cell lysates were
run on SDS-PAGE gels and analyzed by western blotting with rabbit anti-gp120 polyclonal
sera (provided by J. Sodroski).
Cell-cell fusion assay
Env mediated fusion was quantitated as described previously (Gorry et al., 2002). Briefly, 293T
cell cotransfected with pCR3.1Env and pLTR-Tat were mixed with Cf2-Luc cells cotransfected
with 0.05 (low), 0.5 (med), or 5 μg (hi) amounts of pcDNA3-CD4 and pcDNA3-CCR5 resulting
in low, medium, or high cell surface expression of CD4 and CCR5 as determined by flow
cytometry. Fourteen to 16 h later, cells were harvested and assayed for luciferase activity
(Promega, Madison, WI).
Single round infection with pseudotyped viruses
To screen for functional Env clones, 293T cells were cotransfected with pCR3.1Env and
pNL4.3 envGFP. GFP pseudoviruses were harvested 72 h after transfection and used to infect
JC53 cells. GFP positive cells were detected by fluorescence microscopy 48-72 h after
infection. Luciferase pseudotyped viruses were produced by cotransfection of 293T cells with
pCR3.1Env clones and pNL4.3 envLuc. Luciferase pseudoviruses were harvested 72 h after
transfection and used to infect Cf2 cells transfected with CD4 and either CCR5, CXCR4, or
CCR3. 72 h later, cells were harvested and assayed for luciferase activity. MDM were harvested
and assayed for luciferase activity 6 days after infection with luciferase pseudoviruses.
Virus inhibition and neutralization assays
CCR5 inhibitors AD101 (SCH 350581, provided by Schering-Plough Research Institute,
Kenilworth, NJ.), TAK-779, and 2D7 (both obtained through the AIDS Research and
Reference Reagents Program, Division of AIDS, NIAID, NIH, Bethesda, MD.) were
preincubated with Cf2/CD4/R5 target cells for 1 h prior to infection with luciferase
pseudoviruses. For T20 (from Roche, obtained through the AIDS Research and Reference
Reagents Program) and human monoclonal Abs against HIV Env, virus was incubated with
for 1 h with a range of concentrations of T20 or each MAb prior to infection of Cf2/CD4/R5
cells. 72 h later, cells were harvested and assayed for luciferase activity. MAb b12 (Roben et
al., 1994) and 2F5 (Buchacher et al., 1994;Purtscher et al., 1994) were obtained though the
AIDS Research and Reference Reagents Program (from D. Burton and C. Barbas, and Herman
Katinger respectively). MAbs 17b (Thali et al., 1993) and 19e (Decker et al., 2005) were kindly
provided by J. Robinson (Tulane University Health Sciences Center, New Orleans, La.). HIV-
position patient sera, PS1 and PS2 (Vujcic and Quinnan, 1995), were obtained though the AIDS
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Research and Reference Reagents Program from Dr. Luba Vujcic. PS3 and PS4 were kindly
provided by J. Sodroski.
Phylogenetic analysis
Sequences were aligned using VectorNTI (Invitrogen, Carlsbad, CA) and bootstrapped
phylogenetic trees were created by the neighbor joining method using ClustalX (Thompson et
al., 1997). Trees were visualized using Treeview (Page, 1996). Potential N-linked
glycosylation sites were predicted using N-Glycosite (http://hiv-web.lanl.gov). Sequence
signatures in brain and lymphoid sequence sets were identified using VESPA (http://hiv-
web.lanl.gov) (Korber and Myers, 1992).
Nucleotide sequence accession numbers
Genbank accession numbers for gp160 nucleotide and amino acid sequences are DQ976380-
DQ976434. gp160 sequences from the UK1, UK7 and MACS2 brain viral isolates have been
reported previously (Dunfee et al., 2006b;Gorry et al., 2002). (UK1Br15: AF491740;
UK1Br30: AF491741; UK1Br32: AF491742; MACS2Br4: AF491738; MACS2Br9:
AF491739; MACS2Br13: AF491737).
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Fig 1. Cell-cell fusion mediated by brain and lymphoid Envs
(A) 293T cells expressing brain (red) or lymphoid (blue) Envs from MACS2, MACS3, UK1,
and UK7 or the ADA or YU2 Envs were mixed with Cf2luc cells expressing low, medium
(Med), or high (Hi) levels of CD4 and CCR5 as indicated. Fusion was measured as luciferase
counts in lysed cells following 12 h incubation. Control fusion of 293T cells with pCR3.1 in
place of Env, indicating background levels, is represented by grey diamonds. Luciferase
activity less than 1.5-fold above the background level obtained with the no Env negative control
(pCR3.1) was considered negative. Data are expressed as means of duplicate wells from a
single experiment and are representative of results from 2 to 3 independent experiments. Error
bars represent standard deviations. (B) Fusion activity of brain (open symbols) and lymphoid
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(closed symbols) Envs from MACS2, MACS3, UK1 and UK7 expressed as a ratio of Env-
mediated fusion with cells expressing low compared to high levels of CD4 and medium levels
of CCR5.
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Fig 2. Virus entry mediated by brain and lymphoid Envs
Luciferase reporter viruses were pseudotyped with brain (open symbols) or lymphoid (closed
symbols) Envs from MACS2, MACS3, UK1 and UK7. Entry into Cf2 cells is expressed as a
ratio of virus entry on cells expressing low compared to high levels of CD4 and high levels of
CCR5. Actual values for luciferase counts in cells expressing low or high CD4 ranged from
823-101393, 788-34703, 1053-1072087, and 315-58126 for Envs from MACS2, MACS3,
UK1 and UK7, respectively. Background levels were determined as in Fig. 1.
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Fig 3. gp160 and gp120 expression by brain and lymphoid Env clones
Env expression and processing of gp160 to gp120 in 293T cells detected by Western blot with
anti-gp120 rabbit sera. Positions of gp160 and gp120 bands are indicated on the right.
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Fig 4. Virus entry into macrophages mediated by brain and lymphoid Envs
(A) Luciferase reporter viruses were pseudotyped with brain (open bars) or lymphoid (grey
bars) Envs from MACS2, MACS3, UK1 and UK7. Entry into macrophages was measured as
luciferase counts in lysed cells following incubation for 6 days. Data are expressed as means
from duplicate wells and are representative of results in 2 different donors. Error bars represent
standard deviations. (B) Brain (open symbols) and lymphoid (grey symbols) entry into MDM
(y axis) correlates with levels of fusion between Env-expressing 293T cells and Cf2luc cells
expressing low, medium, or high levels of CD4 and high CCR5 (x axis). Pearson's correlation
coefficient (r2) and p values are shown.
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Fig 5. Phylogenetic analysis of full-length HIV env nucleotide sequences from autopsy tissue
samples and viral isolates
Env sequences amplified directly from brain and lymphoid tissues are color-coded grey and
black, respectively. Env sequences for MACS2, UK1 and UK7 brain viral isolates obtained by
PBMC co-culture are shown in black with the prefix Br. Numbers associated with each branch
are bootstrap values, which represent the number of trees, out of 1000 replicates performed,
in which the same branching order was found. Only values above 900 for the major branches
are shown. Branch lengths are proportional to the amount of sequence divergence. Scale bars
indicate 1% sequence divergence. FL, frontal lobe; BG, basal anglia; LN, lymph node; SP,
spleen.
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Fig 6. Amino acid alignment of HIV Env V3 loop regions of brain and lymphoid Env clones with
the clade B consensus
Tissue of origin and number of clones with each sequence are indicated to the left and right of
each sequence, respectively. Numbering is relative to the Hxbc2 Env sequence. Dots indicate
residues identical to the clade B consensus, and dashes indicate gaps. Proline at position 308
is shaded in grey. LN, lymph node; SP, spleen.
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Fig 7. Fusion and entry of brain Envs with a proline to histidine substitution at position 308
(A) 293T cells or luciferase reporter viruses pseudotyped with wild type and mutant brain Envs
from MACS2 (8–12) and UK7 (Br34) were mixed with Cf2luc or Cf2 cells, respectively,
expressing low, medium, or high levels of CD4 and CCR5 as indicated. Fusion and infection
were measured as luciferase counts in lysed cells following 12 or 72 h incubation, respectively.
Background levels were determined as in Fig. 1. (B) Wild type and mutant Env expression and
processing of gp160 to gp120 in 293T cells detected by Western blot with anti-gp120 rabbit
sera. Positions of gp160 and gp120 bands are indicated on the right. (C) Luciferase reporter
viruses pseudotyped with wild type and mutant brain Envs from MACS2 (8–12) and UK7
(Br34) were used to infect MDM from 2 representative donors. Entry was measured as
luciferase counts in lysed cells following 6 days incubation. Data are expressed as means from
duplicate wells. Error bars represent standard deviations.
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TABLE 2
Predicted N-linked glycosylation sites in Env clones from brain and lymphoid tissue
V1 V2 V3 V4 gp120 gp41
MACS2 Brain 1 1 1 5 23 5
Lymphoid 1 2 1 5 25 5
MACS3 Brain 2 2 1 5 26 5
Lymphoid 2 2 1 4 25 4
UK1 Brain 4 2 1 6 27 5
Lymphoid 4 2 1 6 27 5
UK7 Brain 2 2 1 4 25 4
Lymphoid 1 2 1 4 23 4
Shown is the median number of predicted N-linked glycosylation sites in all Envs from the indicated tissue.
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TABLE 3
Neutralization of pseudotyped luciferase viruses by entry inhbitors, MAbs, and HIV-infected patient sera
AD101a TAK779a 2D7b T20b b12b 2F5b PS1c PS2c PS3c PS4c
MACS2 8-12 24.7 354 0.56 0.32 5.22 12.2 >50 393 128 131
8-12/308H 29.8 380 0.53 0.35 4.53 10.3 >50 219 147 200
UK7 Br34 110.3 357 3.44 0.43 0.14 10.3 >50 101 >50 >50
Br34/308H 179.7 324 4.20 0.61 0.14 10.8 >50 143 >50 >50
IC50 titers at which luciferase production was reduced by 50%.
a
nM,
bμg/ml,
c
reciprocal serum dilution
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